Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study.
暂无分享,去创建一个
H. Dombret | H. Tilly | S. Chevret | C. Bastard | C. Preudhomme | P. Fenaux | X. Thomas | F. Bauters | E. Archimbaud | L. Degos | M. Simon | B. Dupriez | M. Renoux | D. Bordessoule | M. Janvier | T. de Revel | S. Castaigne | J. Miclea
[1] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[2] J. Buckley,et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.
[3] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .
[4] H. Dombret,et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation , 2000, Leukemia.
[5] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.
[6] H. Dombret,et al. Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial) , 1999, Leukemia.
[7] W. Hiddemann,et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. , 1999, Blood.
[8] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[9] M. Grever,et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.
[10] J. Buckley,et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. , 1996, Blood.
[11] O. Garson,et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.
[12] Shaun Parsons,et al. Improved survival for patients with acute myelogenous leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Fenaux,et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[15] H. Tilly,et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. , 1993, Leukemia.
[16] C. Coltman,et al. Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance. , 1992, Leukemia.
[17] A. Bartolucci,et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .
[19] P. Ritch,et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. , 1992, Blood.
[20] H. Gralnick,et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.
[21] P. Fenaux,et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. , 1991, Blood.
[22] J. Gabrilove,et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. , 1991, Blood.
[23] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Desai,et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. , 1990, Leukemia.
[25] J. Matthews,et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. , 1990, Blood.
[26] R. Donehower,et al. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. , 1989, Blood.
[27] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[28] J. Karp,et al. Growth response of residual leukemia after initial drug therapy. , 1986, Cancer research.
[29] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[30] D. Catovsky,et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[31] J. Karp,et al. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. , 1984, Blood.
[32] J. Karp,et al. A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. , 1980, Blood.
[33] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[34] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[35] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .